Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01302886 · ClinicalTrials.gov registry record · Phase 2
Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT01302886 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 41 participants.
The verdict
NCT01302886, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
This study will assess the antimyeloma effects of BHQ880A in patients with smoldering multiple myeloma with high risk of progression to active multiple myeloma. BHQ880 will be administered every 28 days in previously untreated patients. Disease assessments will be performed monthly and effects on bone metabolism will be assessed by measurement of serum and urine bone biomarkers, changes in BMD , and QCT with FEA. Additionally, the PK profile of BHQ880 as a single agent and following multiple doses will be obtained.
Interventions
- DRUG BHQ880
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2011-05 |
| Est. Completion | 2013-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01302886
The ClinicalTrials.gov registry entry for NCT01302886 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BHQ880 is the first listed.
NCT01302886 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01302886 about?
NCT01302886 is a clinical study titled "Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma". This study will assess the antimyeloma effects of BHQ880A in patients with smoldering multiple myeloma with high risk of progression to active multiple myeloma. BHQ880 will be administered every 28 days in previously untreated patients. Disease assessments will be performed monthly and effects on bo...
What is the current status of trial NCT01302886?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2011-05. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01302886?
The interventions under investigation include: BHQ880 (DRUG).
Who is sponsoring clinical trial NCT01302886?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.